$139 Million is the total value of ACUTA CAPITAL PARTNERS, LLC's 31 reported holdings in Q3 2019. The portfolio turnover from Q2 2019 to Q3 2019 was 220.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| ARVN | Buy | ARVINAS INC | $12,208,000 | +0.8% | 566,500 | +2.8% | 8.81% | +104.5% |
| AXSM | Buy | AXSOME THERAPEUTICS INC | $10,575,000 | -6.1% | 522,500 | +19.4% | 7.63% | +90.5% |
| MIST | Buy | MILESTONE PHARMACEUTICALS IN | $6,891,000 | -26.9% | 369,500 | +6.5% | 4.97% | +48.5% |
| XENE | Buy | XENON PHARMACEUTICALS INC | $6,330,000 | -8.5% | 702,500 | +0.1% | 4.57% | +85.7% |
| CRSP | Buy | CRISPR THERAPEUTICS AGnamen akt | $5,493,000 | +47.6% | 134,000 | +69.6% | 3.96% | +199.7% |
| BLU | New | BELLUS HEALTH INC NEW | $5,016,000 | – | 785,000 | +100.0% | 3.62% | – |
| RETA | New | REATA PHARMACEUTICALS INCcl a | $3,613,000 | – | 45,000 | +100.0% | 2.61% | – |
| KPTI | New | KARYOPHARM THERAPEUTICS INC | $2,285,000 | – | 237,500 | +100.0% | 1.65% | – |
| AMRN | New | AMARIN CORP PLCspons adr new | $1,516,000 | – | 100,000 | +100.0% | 1.09% | – |
| KURA | New | KURA ONCOLOGY INC | $1,441,000 | – | 95,000 | +100.0% | 1.04% | – |
| ZYME | New | ZYMEWORKS INC | $1,302,000 | – | 52,500 | +100.0% | 0.94% | – |
| RARX | New | RA PHARMACEUTICALS INC | $1,301,000 | – | 55,000 | +100.0% | 0.94% | – |
| MRUS | New | MERUS N V | $1,234,000 | – | 69,274 | +100.0% | 0.89% | – |
| PTCT | New | PTC THERAPEUTICS INC | $1,218,000 | – | 36,000 | +100.0% | 0.88% | – |
| APLT | New | APPLIED THERAPEUTICS INC | $912,000 | – | 83,000 | +100.0% | 0.66% | – |
| SNSS | New | SUNESIS PHARMACEUTICALS INC | $288,000 | – | 400,000 | +100.0% | 0.21% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2019-11-14
Signatures
The EDGAR filing(s) were signed by:
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| IOVANCE BIOTHERAPEUTICS INC | 24 | Q1 2023 | 21.2% |
| IRIDEX CORP | 20 | Q3 2019 | 8.1% |
| ARROWHEAD PHARMACEUTICALS INC | 20 | Q2 2023 | 7.9% |
| IMMUNOMEDICS INC | 19 | Q3 2020 | 20.6% |
| VERACYTE INC | 19 | Q3 2019 | 10.1% |
| ASCENDIS PHARMA A S | 18 | Q2 2020 | 7.2% |
| XENON PHARMACEUTICALS INC | 18 | Q3 2022 | 4.6% |
| CAS MED SYS PAR $0.004 | 18 | Q1 2019 | 6.4% |
| APELLIS PHARMACEUTICALS INC | 17 | Q3 2023 | 18.4% |
| KURA ONCOLOGY INC. COMMON STOCK | 17 | Q3 2023 | 8.1% |
View ACUTA CAPITAL PARTNERS, LLC's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| BCLS Acquisition Corp.Sold out | February 14, 2023 | 0 | 0.0% |
| Jiya Acquisition Corp.Sold out | February 14, 2023 | 0 | 0.0% |
| VistaGen Therapeutics, Inc.Sold out | February 14, 2023 | 0 | 0.0% |
| Larimar Therapeutics, Inc.Sold out | February 15, 2022 | 0 | 0.0% |
| CATALYST BIOSCIENCES, INC.Sold out | February 14, 2022 | 0 | 0.0% |
| Aadi Bioscience, Inc. | September 07, 2021 | 1,529,402 | 7.2% |
| Kadmon Holdings, Inc. | February 14, 2020 | 7,373,333 | 4.6% |
| IRIDEX CORPSold out | November 13, 2019 | 0 | 0.0% |
| ASSEMBLY BIOSCIENCES, INC. | February 14, 2019 | 718,500 | 2.8% |
| CAS MEDICAL SYSTEMS INC | February 14, 2019 | 5,263,508 | 18.2% |
View ACUTA CAPITAL PARTNERS, LLC's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-05-15 |
| 13F-HR | 2024-02-14 |
| 13F-HR | 2023-11-14 |
| 13F-HR | 2023-08-14 |
| 13F-HR | 2023-05-15 |
| SC 13G/A | 2023-02-14 |
| SC 13G/A | 2023-02-14 |
| SC 13G/A | 2023-02-14 |
| 13F-HR | 2023-02-14 |
| 13F-HR | 2022-11-14 |
View ACUTA CAPITAL PARTNERS, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.